| Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma J Larkin, PA Ascierto, B Dréno, V Atkinson, G Liszkay, M Maio, M Mandalà, ... New England Journal of Medicine 371 (20), 1867-1876, 2014 | 2388 | 2014 |
| Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ... New England Journal of Medicine 377 (19), 1824-1835, 2017 | 2226 | 2017 |
| Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ... New England Journal of Medicine 371 (20), 1877-1888, 2014 | 2000 | 2014 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ... New England Journal of Medicine 378 (19), 1789-1801, 2018 | 1783 | 2018 |
| Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial CS Fuchs, T Doi, RW Jang, K Muro, T Satoh, M Machado, W Sun, SI Jalal, ... JAMA oncology 4 (5), e180013-e180013, 2018 | 1664 | 2018 |
| Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ... The Lancet 386 (9992), 444-451, 2015 | 1551 | 2015 |
| Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma GV Long, A Hauschild, M Santinami, V Atkinson, M Mandalà, ... New England Journal of Medicine 377 (19), 1813-1823, 2017 | 1517 | 2017 |
| Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma C Robert, JJ Grob, D Stroyakovskiy, B Karaszewska, A Hauschild, ... New England Journal of Medicine 381 (7), 626-636, 2019 | 1189 | 2019 |
| Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ... The Lancet 392 (10142), 123-133, 2018 | 1154 | 2018 |
| Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial PA Ascierto, GA McArthur, B Dréno, V Atkinson, G Liszkay, ... The lancet oncology 17 (9), 1248-1260, 2016 | 1111 | 2016 |
| Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up R Labianca, B Nordlinger, GD Beretta, S Mosconi, M Mandalà, ... Annals of oncology 24, vi64-vi72, 2013 | 1110 | 2013 |
| Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial R Dummer, PA Ascierto, HJ Gogas, A Arance, M Mandala, G Liszkay, ... The Lancet Oncology 19 (5), 603-615, 2018 | 998 | 2018 |
| Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo … G Agnelli, G Gussoni, C Bianchini, M Verso, M Mandalà, L Cavanna, ... The lancet oncology 10 (10), 943-949, 2009 | 737 | 2009 |
| Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study GV Long, KT Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, ... Annals of Oncology 28 (7), 1631-1639, 2017 | 728 | 2017 |
| Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines M Mandala, A Falanga, F Roila Annals of oncology 22, vi85-vi92, 2011 | 713 | 2011 |
| International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer D Farge, P Debourdeau, M Beckers, C Baglin, RM Bauersachs, B Brenner, ... Journal of Thrombosis and Haemostasis 11 (1), 56-70, 2013 | 688 | 2013 |
| Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label … R Dummer, PA Ascierto, HJ Gogas, A Arance, M Mandala, G Liszkay, ... The Lancet Oncology 19 (10), 1315-1327, 2018 | 585 | 2018 |
| Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial R Dummer, D Schadendorf, PA Ascierto, A Arance, C Dutriaux, ... The Lancet Oncology 18 (4), 435-445, 2017 | 469 | 2017 |
| 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer D Farge, C Frere, JM Connors, C Ay, AA Khorana, A Munoz, B Brenner, ... The Lancet Oncology 20 (10), e566-e581, 2019 | 455 | 2019 |
| Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled … PA Ascierto, M Del Vecchio, M Mandalá, H Gogas, AM Arance, S Dalle, ... The Lancet Oncology 21 (11), 1465-1477, 2020 | 447 | 2020 |
